New combo therapy aims to tame rare bleeding disorder
NCT ID NCT07421167
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new biologic drug called ianalumab combined with a standard platelet-boosting drug (TPO-RA) in people with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. The trial includes 164 adults who have tried at least one prior treatment. The main goal is to see how well patients tolerate the combination over 16 weeks, with a focus on side effects and treatment interruptions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ianalumab (a biologic drug) combined with a thrombopoietin receptor agonist (TPO-RA, a drug that boosts platelet production)
What this could lead to
If successful, this combination could offer a new treatment option for people with immune thrombocytopenia (ITP) whose disease is not well controlled with current therapies.
What could go wrong
This is an early-phase (Phase 2) study with a moderate number of participants (164). It primarily measures tolerability, not long-term effectiveness. Side effects from the combination are possible, and results may not apply to all ITP patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
DH Cancer Research Center LLC
RECRUITINGMargate, Florida, 33063, United States
Contact Email: •••••@•••••
Contact
-
Hope And Healing Care
RECRUITINGHinsdale, Illinois, 60521, United States
Contact Email: •••••@•••••
Contact
-
Summit Medical Group
RECRUITINGSummit, New Jersey, 07901, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••